Formation of a potent antibody (Ab) response following vaccination is considered to be a correlate of protective immunity. Chemotherapy can result in immunological memory loss, by means of diminished antibody (Ab) titers, which is also observed in pediatric Acute Lymphoblastic Leukemia (ALL) patients 1 . In line with this, we have earlier found a link between diminished protective specific Ab titers and loss of bone marrow plasma cells (BMPCs) after completion of pediatric ALL therapy 2 . Some patients also fail to mount protective titers despite re-vaccination 1 . Duration and intensity of chemotherapy in relation to defective mounting and/or maintenance of immunological memory is unknown. Furthermore it is not clear which cellular compartment(s) of the adaptive immunity are mostly affected and contribute to the defective titers, as formation of optimal B cell responses commonly require T cell help. B cell memory constitutes of both circulating antigen-specific Abs, produced by BMPCs, as well as antigen-specific memory B cells (MBCs) that can differentiate to Absecreting cells (ASCs) if a pathogen evades the pre-existing Ab repertoire 3 . Helper T cell populations can be divided into naïve and memory where the latter consists of two large subsets with distinct phenotype, migratory capacity and function 4, 5 . Central memory T cells (T CM ) are believed to mainly recirculate to lymph nodes and lack immediate effector functions, while effector memory T cells (T EM ) primarily home to peripheral sites and possess immediate effector functions 3, 4 .
To in a more comprehensive and systematic manner address the effects of chemotherapy on different cellular components of immunological memory, we developed a novel rhesus macaque model and used the cytotoxic drug, Doxorubicin (Dx), which is widely included in human treatment protocols against a large number of neoplasms. Ten adult rhesus macaques, which were serologically verified as measles-immune but tetanus and rubella naïve, were included in the study. The animals were divided into two groups (n=5 per group) with matched weight and baseline anti-measles IgG titers (fig 1) . It has previously been shown that several cytotoxic drugs induce more severe effects on B compared to T cells in peripheral blood 8 , and that memory T cells are preserved 4A-B) .
Likewise, rubella-specific MBC frequencies were also significantly lower in the treated group initially, and their subsequent enrichment over time was somewhat smaller ( fig 4C) . Tetanusspecific MBCs also expanded slower in the treated group initially, but later on to the same extent in both groups ( fig 4D) . A smaller size of responding B cell clones upon immunization might be one reason behind altered expansion and kinetics in Dx treated animals compared to
controls. Yet, Dx treated animals had a relatively preserved ability to form MBCs against de novo antigens which might be explained by a GC response sustained long enough to allow B cell recovery. In mice, it has been demonstrated that functional GCs can be sustained for up to 8 months after vaccination 13 .
We asked if the robust IgG response to vaccinations observed in Dx treated animals during B cell recovery phase also could convert to long-lived memory. This conversion occurs when Ab production shifts from peripheral plasma blasts to long-lived BMPCs and appears variable and dependent on type of antigen 14 . In our study, we noticed that rubella-specific BMPCs formed equally well in both groups ( fig 4E) , and both rubella and measles IgG titers correlated strongly to the corresponding specific BMPCs already 4 months after vaccination (measles: spearman r = 0.80, p = 0.014; rubella: r = 0.90, p = 0.0046), which implies a conversion to long-term immunity. The correlation was equally strong in both Dx treated and control animals, demonstrating a preserved ability to mount a long-term vaccine response during B cell recovery phase after chemotherapy. If these findings translate into cancer patients, vaccine responses post chemotherapy should be followed-up and assessed for a longer period of time. It should be emphasized however that our nonhuman primate study here does not take into account that previous chemotherapy treatment(s) in humans or disease per se possess suppressive effects on the adaptive immune system. 
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